Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge
- PMID: 35536538
- DOI: 10.1007/s12539-022-00523-1
Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge
Abstract
Purpose: The identification of potential kinase inhibitors plays a key role in drug discovery for treating human diseases. Currently, most existing computational methods only extract limited features such as sequence information from kinases and inhibitors. To further enhance the identification of kinase inhibitors, more features need to be leveraged. Hence, it is appealing to develop effective methods to aggregate feature information from multisource knowledge for predicting potential kinase inhibitors. In this paper, we propose a novel computational framework called FLMTS to improve the performance of kinase inhibitor prediction by aggregating multisource knowledge.
Method: FLMTS uses a random walk with restart (RWR) to combine multiscale information in a heterogeneous network. We used the combined information as features of compounds and kinases and input them into random forest (RF) to predict unknown compound-kinase interactions.
Results: Experimental results reveal that FLMTS obtains significant improvement over existing state-of-the-art methods. Case studies demonstrated the reliability of FLMTS, and pathway enrichment analysis demonstrated that FLMTS could also accurately predict signaling pathways in disease treatment.
Conclusion: In conclusion, our computational framework of FLMTS for improving the prediction of potential kinase inhibitors successfully aggregates feature information from multisource knowledge, yielding better prediction performance than existing state-of-the-art methods.
Keywords: Feature learning; Heterogeneous network; Kinase inhibitor; Multisource knowledge.
© 2022. International Association of Scientists in the Interdisciplinary Areas.
Similar articles
-
Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors.PLoS Comput Biol. 2017 Aug 7;13(8):e1005678. doi: 10.1371/journal.pcbi.1005678. eCollection 2017 Aug. PLoS Comput Biol. 2017. PMID: 28787438 Free PMC article.
-
Ensemble Prediction of Synergistic Drug Combinations Incorporating Biological, Chemical, Pharmacological, and Network Knowledge.IEEE J Biomed Health Inform. 2019 May;23(3):1336-1345. doi: 10.1109/JBHI.2018.2852274. Epub 2018 Jul 2. IEEE J Biomed Health Inform. 2019. PMID: 29994408
-
Exploring Molecular Descriptors and Fingerprints to Predict mTOR Kinase Inhibitors using Machine Learning Techniques.IEEE/ACM Trans Comput Biol Bioinform. 2021 Sep-Oct;18(5):1902-1913. doi: 10.1109/TCBB.2020.2964203. Epub 2021 Oct 7. IEEE/ACM Trans Comput Biol Bioinform. 2021. PMID: 31905145
-
Comprehensive review and assessment of computational methods for predicting RNA post-transcriptional modification sites from RNA sequences.Brief Bioinform. 2020 Sep 25;21(5):1676-1696. doi: 10.1093/bib/bbz112. Brief Bioinform. 2020. PMID: 31714956 Review.
-
Drug-Target Interactions: Prediction Methods and Applications.Curr Protein Pept Sci. 2018;19(6):537-561. doi: 10.2174/1389203718666161108091609. Curr Protein Pept Sci. 2018. PMID: 27829350 Review.
Cited by
-
Speos: an ensemble graph representation learning framework to predict core gene candidates for complex diseases.Nat Commun. 2023 Nov 8;14(1):7206. doi: 10.1038/s41467-023-42975-z. Nat Commun. 2023. PMID: 37938585 Free PMC article.
References
-
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934. https://doi.org/10.1126/science.1075762 - DOI - PubMed
-
- Levitzki A (2003) Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 36(6):462–469. https://doi.org/10.1021/ar0201207 - DOI - PubMed
-
- Muller S, Chaikuad A, Gray NS, Knapp S (2015) The ins and outs of selective kinase inhibitor development. Nat Chem Biol 11(11):818–821. https://doi.org/10.1038/nchembio.1938 - DOI - PubMed
-
- Bhullar KS et al (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 17(1):48. https://doi.org/10.1186/s12943-018-0804-2 - DOI - PubMed - PMC
-
- Roskoski R Jr (2021) Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharm Res 165:105463. https://doi.org/10.1016/j.phrs.2021.105463 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources